Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Feb 28, 2004 3:00pm
470 Views
Post# 7133603

RE: Bilo, misinterpretation re: Prostate NR

RE: Bilo, misinterpretation re: Prostate NRBilo, you are jumping to conclusions that are not supportable by the facts given by ONC. interesting that if there were more than 6 patients enrolled why there is absolutely nothing contained in the "final" nr on the subject to suggest it, and onc has failed to have reuters correct their version which clearly leaves the impression there are only 6. " The study involved six patients who received a single injection of Reolysin and were monitored for about three weeks." https://biz.yahoo.com/rc/040227/health_oncolytics_1.html could it possibly be that for unexplained reasons they decided to end the prostate trials a year after the interim results without anything of substance to add to the interim report, and so they decided they better have some additional news (UK trial) to release with it, otherwise their mis-handling of this trial would be way too transparent? you have no facts to support there were more than 6 - because onc didn't give you any - these guys are wordsmiths when it comes to releases - remember they made the ph 1 glio halt issued days before Xmas sound positive with all the stuff about how safe it was without then explaining why if it was safe they had to stop the ph I safety trials? of course that halt only lasted 6 months - that is immaterial considering the length of that trial so i guess we'll just ignore that, huh?
Bullboard Posts